Table 1.
Characteristics of individuals developing COVID-19 by disease type
| ADTKD-MUC1 | ADTKD-UMOD | |||||
|---|---|---|---|---|---|---|
| COVID-19 infection | Yes | No | P -value | Yes | No | P-value |
| Individuals (n(%))a | 19 (22%) | 64 (88%) | -- | 14 (11%) | 111 (89%) | -- |
| Gender (n male (%)) | 11(58%) | 24 (38%) | 0.079 | 2 (14%) | 44 (40%) | 0.063 |
| Age, years (mean ± sd (median) | 49.6 ± 19.9 (50.6) | 51.6 ± 16.8 (55.6) | 0.63 | 47.0 ± 13.3 (49.5) | 51.6 ± 14.0 (52.8) | 0.14 |
| Age > 60 (n (%)) | 6 (32%) | 22 (34%) | 0.99 | 1 (7%) | 37 (33%) | 0.029 |
| Body mass index, kg/m2 (mean ± sd (median)) | 25.5 ± 5.6 (24) | 25.1 ± 5.0 (24.5) | 0.76 | 24.9 ± 4.5 (24.5) | 25.9 ± 5.1 (25) | 0.47 |
| Active Cancer Diagnosis b | 0 | 0 | -- | 0 | 1 (1%)b | 0.72 d |
| Diabetesc | 0 | 0 | -- | 0 | 1 (1%)c | 0.72 d |
| Chronic obstructive pulmonary disease/asthma | 0 | 1 (2%) | 0.58 d | 0 | 1 (1%) | 0.72 d |
| Hyperlipdemia at risk for cardiovascular disease | 0 | 4 (6%) | 0.26 d | 2 (14%) | 11 (10%) | 0.61 |
| Current Smoker | 0 | 1 (2%) | 0.26 d | 0 | 8 (7%) | 0.30 d |
| eGFRe (mean ± sd (median)) for pre-kidney failure, non-kidney transplanted | 49.7 ± 32.5 (42.6) | 49.4 ± 37.5 (37.6) | 0.98 | 43.9 ± 22.4 (37.5) | 46.2 ± 29.8 (41.7) | 0.77 |
| eGFR > 60 ml/min/1.73m2 (n, column percent) | 2 (11%) | 8 (13%) | 0.52 | 3 (21%) | 15 (14%) | 0.33 |
| eGFR 30 to ≤ 60 ml/min/1.73m2 (n, column percent) | 5 (28%) | 8 (13%) | 4 (29%) | 29 (26%) | ||
| eGFR < 30 ml/min/1.73m2 (n, column percent) and not kidney failure | 2 (11%) | 11 (17%) | 3 (21%) | 21 (19%) | ||
| Transplanted | 9 (50%) | 36 (56%) | 4 (29%) | 44 (40%) | ||
| Receiving dialysis | 0 | 1 (2%) | 0 | 1(1%) | ||
| Duration kidney failure to COVID or time of survey | 14.2 ± 14.5 (11.5) | 17.1 ± 13.0 (17) | 0.57 | 4.4 ± 4.9 (2.6) | 10.8 ± 8.3 (10) | 0.014 |
| Pre-kidney failure | 10 (53%) | 27 (42%) | 0.30 | 10 (71%) | 66 (60%) | 0.44 |
| Duration kidney failure < 10 years | 4 (21%) | 14 (22%) | 3 (21%) | 21 (19%) | ||
| Duration kidney failure 10 to < 15 years | 2 (11%) | 2 (3%) | 1 (7%) | 11 (10%) | ||
| Duration kidney failure 15 to < 20 years | 0 | 5 (8%) | 0 | 6 (5%) | ||
| Duration kidney failure > 20 years | 3 (16%) | 16 (25%) | 0 | 7 (11%) | ||
| No vaccination (n (percent of those reporting vaccination status)) | 3 (16%) | 1 (2%) | 0.040d | 3 (21%) | 12 (11%) | 0.24e |
| Partial vaccination (n (percent of those reporting vaccination status)) | 1 (5%) | 2 (3%) | 1 (7%) | 0 | ||
| Full vaccination (n (percent of those reporting vaccination status)) | 15 (79%) | 59 (95%) | 10 (71%) | 95 (89%) | ||
| Full vaccination and 3rd dose (n (percent of those with full vaccination)) | 5 (33%) | 26 (44%) | 0.49 | 2 (20%) | 40 (42%) | 0.18 |
aPercentages in the first row represent row percent. For other rows in the table, column percentages are given
bNon-Hodgkins Lymphoma
CType 1 Diabetes Mellitus
dP-values calculated using permutation test
eEstimated glomerular filtration rate